NeuroScientific Biopharmaceuticals (NSB) H2 2026 earnings summary

Executive summary

• Focused on R&D of biomedical products for neurodegenerative and immune-mediated diseases, with major progress on the StemSmart™ mesenchymal stem cell (MSC) platform and planning for Phase 2 clinical trials in Crohn's disease.

• Received positive clinical outcomes for StemSmart™ in fistulising Crohn's disease under the TGA's Special Access Scheme, with 4 of 5 patients achieving clinical response and no serious adverse events.

• Strategic review led to discontinuation of independent development of EmtinB for glaucoma, shifting to out-licensing and partnership opportunities.

• Appointed new CEO and CMO to strengthen leadership for ongoing development activities.

Financial highlights

• Total income increased 278.98% year-over-year to $629,398, mainly due to a $402,659 R&D tax incentive.

• Net loss after tax widened to $4,693,164 from $1,845,513 year-over-year, reflecting increased R&D and corporate costs.

• Cash and term deposit balances at year-end were $4,629,924, down from $7,265,769 the prior year.

• Cash outflow from operating activities was $2,778,123, up from $1,125,252 year-over-year.

• No dividends declared or paid for the year.

Outlook and guidance

• Net losses after tax are expected to continue as clinical development and GMP manufacturing of StemSmart™ progresses.

• Directors are confident that current cash reserves are sufficient to fund forecast expenditure for at least twelve months from the report date.